2. Vitamin D Related/Nuclear Receptor
  3. Thyroid Hormone Receptor
  4. ALG-055009

ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC50 of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease.

For research use only. We do not sell to patients.

ALG-055009

ALG-055009 Chemical Structure

CAS No. : 2542029-03-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

ALG-055009 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC50 of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease[1].

IC50 & Target[1]

THR-β

0.063 μM (EC50)

Cellular Effect
Cell Line Type Value Description References
Huh-7 EC50
9 nM
Compound: 14
Effect on CPT1A gene expression in human Huh-7 cells measured for 24 hrs
Effect on CPT1A gene expression in human Huh-7 cells measured for 24 hrs
[PMID: 39221768]
In Vitro

ALG-055009 (Compound 14) (1 h) potently activates recombinant human THR-β with an EC50 of 0.063 μM and shows 5.7-fold selectivity for THR-β over recombinant human THR-α in a TR-FRET coactivator biochemical assay[1].
ALG-055009 (18-24 h) activates THR-β in transfected HEK293T cells with an EC50 of 0.050 μM and shows 3.8-fold selectivity for THR-β over THR-α in a luciferase reporter gene assay[1].
ALG-055009 (24 h) induces CPT1A gene expression in Huh-7 liver-derived cells with an EC50 of 9 nM, demonstrating potent on-target activity related to mitochondrial fatty acid β-oxidation[1].
ALG-055009 (1 μM; 0-180 min) shows high metabolic stability in cryopreserved mouse, rat, dog, cynomolgus monkey, and human hepatocytes[1].
ALG-055009 has low CYP450 inhibition potential in human liver microsomes, with an IC50 of 112 μM for CYP2C8, 37 μM for CYP2C9, and IC50 values >50 μM for CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4[1].
ALG-055009 (0.07-50 μM; 10 min) weakly inhibits recombinant human UGT1A1 with an IC50 of 37.5 μM, indicating low risk of glucuronidation-related drug-drug interactions[1].
ALG-055009 (5 μM; 1 h) shows good permeability across Caco-2 cell monolayers with an A to B Papp of 2.2 × 10-6 cm/s and a low efflux ratio of 6[1].
ALG-055009 (2 μM; 4 h) shows high plasma protein binding (>96%) in mouse, rat, dog, cynomolgus monkey, and human plasma[1].
ALG-055009 (5 μM; 60 min) has blood-to-plasma ratios of 0.49 to 0.64 in mouse, rat, dog, cynomolgus monkey, and human whole blood, showing no preferential red blood cell partitioning[1].
ALG-055009 is neither a substrate nor an
inhibitor (IC50 = 34.4 and 23.8 μM, respectively) of BCRP or
OATP1B1[1].
ALG-055009 (up to 10 μM) shows no inhibition of human Nav1.5, Cav1.2, or hERG potassium channels at concentrations up to 10 μM, indicating low cardiovascular safety risk[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ALG-055009 Related Antibodies
Parmacokinetics
Species Dose Route CL Vss T1/2 Cmax AUC0-inf F
Mice[1] 5 mg/kg i.v. 3.52 mL/min/kg 0.694 L/kg 2.27 h / 23704 ng·h/mL /
Mice[1] 5 mg/kg p.o. / / 2.97 h 3547 ng/mL 17977 ng·h/mL 75.8 %
Rat[1] 1 mg/kg i.v. 1.40 mL/min/kg 0.627 L/kg 7.22 h / 11957 ng·h/mL /
Rat[1] 5 mg/kg p.o. / / 7.59 h 7560 ng/mL 60124 ng·h/mL 101 %
Rat[1] 0.03 mg/kg p.o. / / / 12.9 ng/mL 117 ng·h/mL 35.1 %
Rat[1] 0.1 mg/kg p.o. / / / 52.7 ng/mL 698 ng·h/mL 62.7 %
Rat[1] 0.3 mg/kg p.o. / / / 249 ng/mL 3651 ng·h/mL 109 %
Dog[1] 1 mg/kg i.v. 0.895 mL/min/kg 0.687 L/kg 10.6 h / 18624 ng·h/mL /
Dog[1] 5 mg/kg p.o. / / 9.26 h 4673 ng/mL 51873 ng·h/mL 55.7 %
Dog[1] 0.03 mg/kg p.o. / / / 4.47 ng/mL 158 ng·h/mL 29.3 %
Dog[1] 0.3 mg/kg p.o. / / 12.9 h 206 ng/mL 4160 ng·h/mL 74.5 %
Cynomolgus Monkey[1] 1 mg/kg i.v. 1.59 mL/min/kg 0.597 L/kg 7.72 h 8107 ng/mL 10987 ng·h/mL /
Cynomolgus Monkey[1] 5 mg/kg p.o. / / 8.03 h / 45735 ng·h/mL 83.3 %
In Vivo

ALG-055009 (Compound 14) (0.015-1.5 mg/kg; p.o.; single dose) produces dose-dependent reductions in serum total cholesterol and LDL-C in high fat diet-fed hypercholesterolemic rats, with a minimum effective dose of 0.075 mg/kg, and induces significant increases in hepatic THR-β target gene expression at doses ≥0.15 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, high fat diet-induced hypercholesterolemia)[1]
Dosage: 0.015 mg/kg; 0.05 mg/kg; 0.075 mg/kg; 0.15 mg/kg; 0.5 mg/kg; 1.5 mg/kg
Administration: p.o.; single dose
Result: Reduced serum total cholesterol by 66.9% at 1.5 mg/kg.
Reduced serum low-density lipoprotein cholesterol by 72.3% at 1.5 mg/kg.
Reduced serum total T3 by 64.7% at 1.5 mg/kg.
Reduced serum total T4 by 63.8% at 1.5 mg/kg.
Increased liver Dio1 gene and Me1 gene expression at 0.075-0.5 mg/kg.
Clinical Trial
Molecular Weight

425.23

Formula

C16H14Cl2N6O4
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

CC(C1=CC(OC2=C(Cl)C=C(N3N=C(C(NC3=O)=O)N)C=C2Cl)=NNC1=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (117.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3517 mL 11.7583 mL 23.5167 mL
5 mM 0.4703 mL 2.3517 mL 4.7033 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3517 mL 11.7583 mL 23.5167 mL 58.7917 mL
5 mM 0.4703 mL 2.3517 mL 4.7033 mL 11.7583 mL
10 mM 0.2352 mL 1.1758 mL 2.3517 mL 5.8792 mL
15 mM 0.1568 mL 0.7839 mL 1.5678 mL 3.9194 mL
20 mM 0.1176 mL 0.5879 mL 1.1758 mL 2.9396 mL
25 mM 0.0941 mL 0.4703 mL 0.9407 mL 2.3517 mL
30 mM 0.0784 mL 0.3919 mL 0.7839 mL 1.9597 mL
40 mM 0.0588 mL 0.2940 mL 0.5879 mL 1.4698 mL
50 mM 0.0470 mL 0.2352 mL 0.4703 mL 1.1758 mL
60 mM 0.0392 mL 0.1960 mL 0.3919 mL 0.9799 mL
80 mM 0.0294 mL 0.1470 mL 0.2940 mL 0.7349 mL
100 mM 0.0235 mL 0.1176 mL 0.2352 mL 0.5879 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ALG-055009 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ALG-0550092542029-03-6ALG055009ALG 055009Thyroid Hormone ReceptorTHRThyroid Hormone Receptor BetaTHR-βTHR-αHEK293-OATP1B1 cellsmetabolic dysfunction-associated steatohepatitisHEK293T cellsCaco-2 cell monolayersCPT1AHuh-7 liver-derived cellshuman hepatocytesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ALG-055009
Cat. No.:
HY-168046
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.